新型冠状病毒S1蛋白亲和多肽的筛选与验证  

Screening and verification of affinity peptide for SARS-CoV-2 spike 1 protein

作　　者：杨芳芳 龙晋蓉 王鑫[2] 李蕾 曹艺明 杨静[2] 王升启[1,2] YANG Fang-fang;LONG Jin-rong;WANG Xin;LI Lei;CAO Yi-ming;YANG Jing;WANG Sheng-qi(Tianjin University of Traditional Chinese Medicine,Tianjin 300139,China;Institute of Radiation Medicine,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100850,China)

机构地区：[1]天津中医药大学,天津300139 [2]军事科学院军事医学研究院辐射医学研究所,北京100850

出　　处：《军事医学》2022年第9期682-685,共4页Military Medical Sciences

基　　金：国家自然科学基金(81830101,81703429)。

摘　　要：目的以新型冠状病毒(SARS-CoV-2)刺突蛋白(S1蛋白)为靶点,筛选抗新冠病毒的多肽类药物。方法以S1蛋白为靶蛋白,利用噬菌体展示技术,从噬菌体随机12肽库中筛选亲和多肽,通过酶联免疫吸附实验(ELISA)验证筛选多肽与靶蛋白的亲和性,并对筛选出的亲和多肽进行细胞水平验证。结果多肽p27与S1蛋白具有较强亲和性,并有阻止SARS-CoV-2假病毒进入细胞的作用,IC50为73μmol/L。结论多肽p27可能有抗SARS-CoV-2活性,具有开发成抗新冠病毒多肽类药物的潜力。Objective To use SARS-CoV-2 spike protein(S protein)as the target to screen anti-SARS-CoV-2-peptide drugs.Methods The SARS-CoV-2 spike protein binding peptides were screened out through affinity selection from a 12-peptide display library,the affinity between the peptides and S protein was verified by enzyme linked immunosorbent assay(ELISA),and the anti-SARS-CoV-2 activity was evaluated in HEK-293T-ACE2 cells.Results p27 had a strong affinity with S1 protein and could prevent SARS-CoV-2 pseudovirus from entering cells with IC50of73μmol/L.Conclusion Peptide p27 may have anti-SARS-COV-2 activity and can be potentially developed into antiSARS-CoV-2.

关 键 词：新型冠状病毒 S1蛋白 噬菌体展示技术 多肽 

分 类 号：R373.19[医药卫生—病原生物学]